Infasurf
PreclinicalSmall molecule
Infasurf is one of 31 small molecule programs targeting Pre-Term. It is currently in Preclinical.
2
Indications
4
Total Trials
0
Active Trials
30
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
27 competitors in Prophylaxis
#DrugCompanyPhaseTrials
1Eliquis
Bristol-Myers SquibbApproved
Cymbalta
Jazz PharmaceuticalsApproved
Coreg
Akero TherapeuticsApproved
Xarelto
WWim Janssens
Approved
Vibramycin
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Lovenox
SanofiPhase 3
Cabenuva
GSKPhase 3
Bayer Aspirin
BayerPhase 3
Lovenox
SanofiPhase 3
Prevymis
CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Prophylaxis1 trial
Pilot Trial of Surfactant Booster Prophylaxis For Ventilated Preterm Neonates
Completed·—·N/A·NCT00208039·89 enrolled
Nitric Oxide1 trial
Pre-Term1 trial
Pilot Trial of Surfactant Therapy For Preterm Neonates 5-21 Days Old With Respiratory Decompensation
Completed·—·N/A·NCT00165074·11 enrolled
Chronic Lung Disease1 trial
Pilot Study of Topical Steroid for Prevention of Chronic Lung Disease in Extremely Premature Infants.
Unknown status·—·Phase 2·NCT01268215·45 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Infasurf. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Preclinical[1]
- Company
- RRoberta Ballard